检索历史 清除

目的:探讨贝伐珠单抗联合紫杉类药物治疗晚期人表皮生长因子受体2（human epidermal growth factor receptor-2，HER-2）阴性乳腺癌患者的效果。方法:以2021年1月至2023年6月于四川绵阳四〇四医院收治的61例晚期HER-2阴性乳腺癌患者为研究对象，将其中给予紫杉醇（白蛋白结合型）治疗的29例患者纳入对照组，将贝伐珠单抗联合紫杉醇（白蛋白结合型）治疗的32例患者纳入观察组。对比分析两组患者临床疗效［客观缓解率（objective response rate，ORR）和疾病控制率（disease control rate，DCR）］、治疗前后肿瘤标志物水平［癌胚抗原、糖类抗原125（carbohydrate antigen-125，CA125）、糖类抗原153（carbohydrate antigen-153，CA153）］、治疗期间不良反应。呈正态分布的计量资料以 xˉ± s表示，组间比较采用 t检验；计数资料比较采用 χ2检验或秩和检验。采用Kaplan-Meier生存曲线分析患者预后情况。 结果:治疗后观察组患者较对照组ORR和DCR明显升高［53.13%（17/32）与27.59（8/29），84.38%（27/32）与62.07%（18/29）］，差异均有统计学意义（ χ2值分别为4.10、3.91，均 P<0.05）；观察组患者治疗后血清癌胚抗原、CA125、CA153较对照组明显降低［癌胚抗原：（15.76 ±1.89）ng/mL与（20.24 ±2.36）ng/mL，CA125：（25.78 ±3.44）kU/L与（34.66 ±4.01）kU/L，CA153：（18.34±2.19）kU/L与（24.19±3.28）kU/L］，两组比较差异均有统计学意义（ t值分别为8.22、9.31、8.26，均 P<0.01）；两组患者治疗期间不良反应发生率比较差异无统计学意义（ P>0.05）；治疗后观察组患者中位疾病无进展期（progression-free survival，PFS）明显长于对照组［8个月与5个月］，两组比较差异有统计学意义（ χ2=7.14， P=0.008）。 结论:贝伐珠单抗联合紫衫类治疗晚期HER-2阴性乳腺癌患者近期疗效确切，可抑制肿瘤标志物表达，延长PFS，具有良好的安全性，值得临床推广应用。

Objective:To investigate the effect of bevacizumab combined with taxanes in the treatment of advanced human epidermal growth factor receptor-2 (HER-2) negative breast cancer.Method:A total of 61 patients with advanced HER-2 negative breast cancer admitted to SiChuan Mianyang 404 Hospital from January 2021 to June 2023 were selected as the research objects, giving one to paclitaxel (albumin combined type) treatment of 29 patients in control group, will be cut bead single combined therapy with paclitaxel (albumin combined type) of 32 patients into the observation group. The clinical efficacy (objective response rate (ORR) and disease control rate (DCR)), the levels of tumor markers (carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (carbohydrate)) before and after treatment were compared between the two groups CA125, carbohydrate antigen 153 (CA153), adverse reactions during treatment; Measurement data with normal distribution were represented as indicated, and comparison between groups was analyzed using the t test. Rate between group compared with chi-square test. The rank sum test was used to compare the constituent ratio of ordinal data between groups. Kaplan-Meier survival curve was used to analyze the prognosis of patients. Results After treatment, the ORR and DCR of the observation group were significantly higher than those of the control group (53.13%(17/32) vs 27.59 (8/29), 84.38% (27/32) vs 62.07% (18/29)), the differences were statistically significant ( χ2=4.10, 3.91, all P<0.05). After treatment, the serum CEA, CA125 and CA153 in the observation group were significantly lower than those in the control group (CEA: (15.76±1.89) ng/mL vs. (20.24±2.36) ng/mL, CA125: (25.78±3.44) kU/L vs (34.66±4.01) kU/L, CA125: (25.78±3.44) kU/L vs. (34.66±4.01) kU/L; CA153: (18.34±2.19) kU/L vs. (24.19±3.28) kU/L). The difference between the two groups was statistically significant ( t-values were 8.22, 9.31, and 8.26, all P<0.01). There was no significant difference in the incidence of adverse reactions between the two groups during treatment ( P>0.05). The median progression-free survival (PFS) of the observation group was significantly longer than that of the control group (8 months vs 5 months, χ2=7.14, P=0.008). Conclusions:Bevacizumab combined with taxanes in the treatment of patients with advanced HER-2 negative breast cancer has definite short-term efficacy, can inhibit the expression of tumor markers, prolong PFS, has good safety, and is worthy of clinical application.